Cullin4A (Cul4A) is a scaffold protein that assembles cullin-RING ubiquitin ligase (E3) complexes and regulates many cellular events, including cell survival, development, growth and cell cycle control. Our previous study suggested that Cul4A is oncogenic in vitro, but its oncogenic role in vivo has not been studied. Here, we used a Cul4A transgenic mouse model to study the potential oncogenic role of Cul4A in lung tumour development. After Cul4A over-expression was induced in the lungs for 32 weeks, atypical epithelial cells were observed. After 40 weeks, lung tumours were visible and were characterized as grade I or II adenocarcinomas. Immunohistochemistry (IHC) revealed decreased levels of Cul4A-associated proteins p21 CIP1 and tumour suppressor p19 ARF in the lung tumours, suggesting that Cul4A regulated their expression in these tumours. Increased levels of p27 KIP1 and p16
Introduction
The Cullin4A gene (Cul4A) is over-expressed or amplified in a variety of human cancers [1] [2] [3] [4] . Association of Cul4A amplification with aggressive tumour growth and poor prognosis has been suggested [5, 6] . Cul4A depletion reportedly increased the protection of mouse skin from ultraviolet-induced carcinogenesis [7] . We previously demonstrated the amplification of Cul4A copy number and the increased expression of Cul4A protein in malignant pleural mesothelioma cells, suggesting that Cul4A is an oncogene in thoracic cancer [8] . However, the oncogenic role of Cul4A in vivo has not been studied.
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using the cBioPortal for Cancer Genomics database (http://www.cbioportal.org) [11, 12] further revealed the up-regulation of Cul4A in 8.3% of lung squamous cell carcinomas (n = 179) and in 6% of lung adenocarcinomas (n = 230) (data not shown). We also found a correlation between Cul4A mRNA expression levels and Cul4A copy number in lung adenocarcinoma cases (see supplementary material, Figure S3 ). Collectively, these results suggest that increased expression of Cul4A is associated with the occurrence of lung cancer in humans, but its oncogenic role in vivo remains to be investigated.
To investigate the biology of the ≥3% of NSCLCs that showed Cul4A over-expression, we developed a Lox-Stop-Lox Cul4A conditional mouse strain (Lox-Cul4A) [13] , in which Cul4A over-expression is activated by the introduction of an engineered adenovirus carrying the Cre recombinase (Ad-Cre) [14] . After Cul4A over-expression was induced, we observed lesions after 24 weeks and visible lung tumours after 40 weeks. Mouse lungs and lung tumours were collected at several time points after Cul4A over-expression and analysed for the expression of Cul4A protein and its associated proteins. Here, we show that Cul4A is oncogenic in vivo and that over-expression of Cul4A leads to tumourigenesis in the mouse lung.
Materials and methods

Induction of Cul4A-over-expression in transgenic mice
All in vivo experiments strictly followed the UCSF institutional guidelines (Institutional Animal Care and Use Committee, Approval No. AN085516-03C). The Cul4A transgenic mice were generated as previously described [13] and were maintained as heterozygotes on an FVB/N background. The engineered adenovirus (Ad) carrying either Cre-recombinase (Ad5CMVCre) or GFP (Ad5CMVeGFP) was purchased from the Gene Transfer Vector Core of the University of Iowa. The adenoviruses were introduced into the 6-10 week-old mice through inhalation to induce Cul4A over-expression in the lung, as previously described [15] . Age-matched littermate mice infected with Ad-GFP were used as controls. Transgenic mice were anaesthetized with 2.5% Avertin via intraperitoneal injection, after which half of the mice inhaled approximately 10 6 or 10 7 particles of Ad-Cre or Ad-GFP directly into the lungs.
Histological and immunohistochemical analysis (IHC) of lung and tumour samples
Lungs from the transgenic mice were collected at 8, 16, 24, 32, 40, Three independent researchers blindly scored positivity, and the data represent the samples that were scored positive by all three individuals. The following scoring system was used: −, no stain; +, weak staining (≥10% stained cellularity considered as positive); ++, moderate staining (≥30% stained cellularity considered as positive); +++, strong staining (≥50% stained cellularity considered as positive). All scoring was done under magnification (×20) with a Zeiss Axioscop 2 microscope (Carl Zeiss, Germany) and photomicrographs were obtained with a Carl Zeiss AxioCam MrC5 camera.
Cell viability assay
The CellTiter-Glo ® luminescent cell viability assay (Promega, Madison, WI, USA) was used to evaluate cisplatin cytotoxicity. H2170 cells were transfected with Cul4A siRNA or control siRNA at 100, 50 or 1 nM, using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. H838 and H460 cells were transfected with Cul4A siRNA or control siRNA at 50 nM. Transfected cells were seeded at 5000 cells/well in 96-well plates and cultured at 37 ∘ C supplied with 5% CO 2 without antibiotics for 24 h. Cells were treated with cisplatin (10-fold serial dilution) for 72 h. Then 50 μl CellTiter-Glo reagent was added into each well. After incubation for 10 min, the luminescence signals were read by a GloMax ® 96 microplate luminometer (Promega, Madison, WI, USA) and a dose-response curve was plotted. The assay was done in triplicate and data are shown as mean ± standard deviation (SD). The half maximal inhibitory concentration (IC 50 ) values were determined using GraphPad Prism ® log (inhibitor) versus response (variable slope) software (v. 6.01, La Jolla, CA, USA). Paired Student's t-tests were used to compare cell viability for different treatments against the samples with cisplatin only. Significance was defined as p < 0.05 with two-sided analysis.
Further details are provided in Supplementary materials and methods (see supplementary material).
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heterozygous transgenic mice over-expressing Cre-inducible Cul4A (Lox-Cul4A) [13] , collected mouse lungs after Cul4A over-expression was induced ( Figure 1A ) and analysed tissue sections from mouse lungs by using IHC. We found that the morphology of Ad-GFP-induced mouse lung appeared to be normal at all time points ( Figure 1B) . In contrast, mice injected with Ad-Cre showed hyperplasia after 8-16 weeks of Cul4A over-expression, as was noted previously [13] . Local oedema was evident at 24 weeks and notably worse at 40 weeks ( Figure 1C ). Multiple aggregations of lymphocytes were observed under the respiratory epithelial lining ( Figure 1D ). The number and size of the lymphocyte aggregations increased after 24 weeks of Cul4A over-expression ( Figure 1E ). We observed small groups of atypical cells at 32 weeks ( Figure 1F ) and larger groups of these cells at 40 weeks ( Figure 1G ), whereas the morphology of the surrounding bronchial epithelium appeared normal. The atypical epithelial cells showed enlarged nuclei and cell size, suggesting that these cells may develop into tumour cells at later time points.
We observed tumours on the surface of 8/25 (32%) mouse lungs after 40 weeks of Cul4A over-expression. One of these eight lungs had two tumours. These nine tumours were in the size range 2.25-25 mm Figure 3A ) and lymphovascular infiltration ( Figure 3B ), suggesting invasive behaviour and spread to the lymphatics. In addition, in the tissue surrounding the major tumour, we observed satellite adenocarcinomas with invasion to adjacent stroma after 64 weeks of Cul4A over-expression ( Figure 3C ). Multiple lymphoid aggregates surrounded the developed adenocarcinoma ( Figure 3D ), suggesting that their appearance is associated with tumour development. These results show that adenocarcinoma growth can be induced in this mouse model and that the tumours have developed invasive behaviour and can multiply in the mouse lung. Moreover, increased expression of Cul4A and the c-Myc tag, which was constructed after the Cul4A transgene, was detected in the mouse lung tumours (see supplementary material, Figure S4A , B). Quantitative analysis of the IHC data for Cul4A, p27 KIP1 , CDT1 and pericentrin showed similar trend of changes in IHC staining intensity between lung tumours and control lungs (see supplementary material, Figure  S4C ). Copy number of the Cul4A transgene in the transgenic mouse tissues was analysed by using qPCR (see supplementary material, Figure S5A ). Similar Cul4A copy number (three or four copies) was detected in the mouse lungs and in the MEFs, whereas the lung tumours showed similar or slightly more Cul4A copy number in the cells.
Decreased expression of p21 CIP1 and increased expression of PCNA in the lung tumours over-expressing Cul4A
To further study the possible mechanism of Cul4A, a component of Cul4A-based E3 ubiquitin ligase complexes, on the development of lung adenocarcinoma, we analysed the expression of several proteins, which are known to associate with Cul4A, in the lungs and tumour samples from mice that over-expressed human Cul4A transgene. The cyclin-dependent kinase (CDK) inhibitor p21 CIP1 has been shown to associate with Cul4A-based E3 ubiquitin ligase complex [16, 17] . We previously demonstrated that Cul4A over-expression resulted in down-regulation of p21 CIP1 protein in mesothelioma cells [8] , suggesting that Cul4A over-expression mediated the degradation of p21 CIP1 in vitro. In this Lox-Cul4A mouse model, p21 CIP1 protein expression in control lungs was strong at every time point ( Figure 4A , inset) but weak in the six tumours examined ( Figure 4A , main figure). Both chromosomal and transcriptional levels of p21 CIP1 measured in the lung tumours and the mouse lungs using qRT-PCR showed similar results (see supplementary material, Figure S5B ), suggesting the decrease in p21 CIP1 expression occurred in the post-translational level. These IHC results suggest that Cul4A over-expression decreased p21 CIP1 expression in the lung tumours, an event which may be associated with lung tumour development in this mouse model. We next used the MEFs from transgenic mice to evaluate the observation of p21 CIP1 degradation driven by Cul4A over-expression. Primary mouse MEFs generated from the transgenic mouse model were infected with Ad-Cre to induce Cul4A over-expression. Afterward, the cells were co-transfected with HA-tagged p21 CIP1 and either Cul4A siRNA or control siRNA. Our results indicate that the expression of p21 CIP1 was increased in the cells when Cul4A expression was knocked down ( Figure 4B) . To test the possible mechanism that decreased p21 CIP1 expression in the lung tumours, we next examined the expression of PCNA, a key co-factor that mediates Cul4A-dependent proteolysis of p21 CIP1 [16, 18] . IHC analysis revealed that PCNA expression was strong in the four lung tumours analysed ( Figure 4C , main figure) but weak in the control lungs ( Figure 4C , inset), suggesting that elevated PCNA expression contributed to Cul4A-mediated p21 CIP1 down-regulation in lung tumourigenesis. 
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that p19
ARF expression was weak in the seven analysed tumours ( Figure 4D, main figure) when compared to that in the control lungs ( Figure 4D, inset) . In contrast, p16
INK4a expression was strong in the lung tumours ( Figure 4E, main figure) but weak in the control lungs ( Figure 4E, inset) .
Increased expression of p27
KIP1 in the lung tumours
Protein p27 KIP1 is a key regulator of cell-cycle progression, and can regulate cell-cycle arrest by inhibiting CDK activity [19] . Protein p27 KIP1 may be a prognostic factor in human cancers [20] [21] [22] and its depletion in mice results in tumour growth [23] . Moreover, Cul4A-based E3 ubiquitin ligase was shown to mediate the expression of p27 KIP1 [24] . In our mouse model, p27 KIP1 expression was strong in the lung tumours over-expressing Cul4A ( Figure 4F, main figure) but moderate in the control lungs ( Figure 4F, inset) . These results suggest that Cul4A over-expression elevated p27 KIP1 expression in lung tumourigenesis. Genomic instability in the lung tumours that over-expressed Cul4A
As a key factor in regulating genetic stability, DNA replication licensing factor CDT1 can also associate with Cul4A-based E3 ubiquitin ligase complexes [25] [26] [27] . To determine whether over-expression of Cul4A resulted in loss of CDT1 expression, we compared CDT1 expression in lung tumours and control lungs by using IHC analysis. Expression of CDT1 was negative in the six lung tumours ( Figure 5A , main figure) but moderate in the control lungs ( Figure 5A , inset). Both chromosomal and transcriptional levels of CDT1 measured in the lung tumours and the mouse lungs by using qRT-PCR showed similar results (see supplementary material, Figure S5C ), suggesting the decrease of CDT1 expression occurred in the post-translational level. We next measured the expression of CDT1 in primary MEFs using western blotting and our results showed that knocking down Cul4A expression using siRNA decreased Cul4A expression but increased CDT1 expression in the cells ( Figure 5B) . Together, the results suggested that CDT1 expression was decreased in the lung tumours over-expressing Cul4A. To test whether genomic instability occurred in the lung tumours, the expression of pericentrin, an indicator of genomic instability [28] , was analysed using IHC. Our data showed that pericentrin expression was strong in the lung tumours ( Figure 5C , main figure) but weak in control lungs ( Figure 5C , inset), suggesting that genomic instability occurred in the lung tumours over-expressing Cul4A. The genomic instability in the tumours that over-express Cul4A was further evaluated using array comparative genomic hybridization (aCGH) to visualize DNA copy number alterations across the lung tumour genomes. The most frequent amplification was on distal chromosome 8 and the most frequent deletion was on proximal chromosome 18 ( Figure 5D ). A Kras transgenic mouse model of lung cancer was developed and genomic instability in the lung tumours was analysed using aCGH [29] . Increase in DNA copy number was detected on multiple chromosomes in the aCGH results collected from Kras over-expressed lung tumours. Similar to our observation of the aCGH data from Cul4A over-expressed lung tumours, increase in DNA copy number was also detected on the chromosome 8 of Kras over-expressed tumours. Genomic instability was also shown in human NSCLC cell lines H2170 (four copies) and H226 (three copies) ( Figure 6A ) analysed by using aCGH [30] . A high level of amplification at 8q24 was identified in both H2170 and H226 cells. Additional amplification was also identified in H2170 cells at 14q13. These results suggest that recurring DNA copy alterations occurred during tumourigenesis in this Cul4A mouse model. However, further study with a larger sample size of tumours is needed to confirm this hypothesis.
A synergistic effect in inhibiting NSCLC by Cul4A knock down and cisplatin treatment
We next examined whether Cul4A over-expression is associated with drug resistance to the chemotherapy drug cisplatin in NSCLC. To test this hypothesis, we knocked down Cul4A expression in NSCLC using RNA interference and then measured the sensitivity of these NSCLC cells to cisplatin treatment. Among the six lung cancer cell lines expressing moderate to high levels of Cul4A compared to the weak Cul4A expression in the normal lung as shown by IHC analysis, the H2170 cell line had the highest copy number of Cul4A when analysed using FISH ( Figure 6A ). We next compared the inhibition effects of cisplatin on H2170 with or without Cul4A siRNA. The inhibition efficiency of RNA interference on Cul4A mRNA transcription was over 94% in four selected cancer cell lines (see supplementary material, Figure S6A ). Viability of H2170 cells was measured after 72 h of cisplatin treatment ( Figure 6B, C) . From the dose-response curve, IC 50 values were calculated in H2170 cells treated with cisplatin and either 100 nM Cul4A siRNA (0.91 ± 5.8 μM), 100 nM control siRNA (2.34 ± 5.5 μM), 1 nM Cul4A siRNA (2.48 ± 5.1 μM) or 1 nM control siRNA (2.31 ± 6.5 μM) ( Figure 6D ). IC 50 values in H2170 cells treated with cisplatin only averaged 3.35 ± 5.3 μM. We further compared the effect of the combination treatment in NSCLC cell lines H460, H838 and H2170, using the combination treatment of 50 nM Cul4A siRNA and cisplatin (see supplementary material, Figure 6B-D) and all the NSCLC cell lines showed increased in their sensitivity to cisplatin when the Cul4A expression was knocked down. From the dose-response curve, the IC 50 values in H2170 cells (higher Cul4A copy number) decreased ∼20% when Cul4A was knocked down, and the IC 50 values in H460 or H838 cell lines (lower Cul4A copy number) was decreased ≤3% when Cul4A was knocked down (see supplementary material, Figure S6E ). Together, these results suggest that the combination treatment of Cul4A knock-down and cisplatin showed a synergistic effect in inhibiting NSCLC cells. 
Discussion
Our study demonstrates that Cul4A is oncogenic in vivo and that the development of lung tumours can be induced by Cul4A over-expression. After Cul4A was over-expressed in lung tumours, the protein levels of p21 CIP1 , p19 ARF and CDT1 decreased, whereas those of p27 KIP1 , p16 INK4a , PCNA and pericentrin increased. Our results suggest that these cellular events contribute to the initiation and development of the lung tumours in the mouse model of Cul4A over-expression, and that the expression of DNA replication licensing factor CDT1 may contribute to genomic instability and tumour development. Our study also showed that in addition to the oncogenic role of Cul4A expression in vivo, knocking down Cul4A expression in lung cancer H2170 cells increased their sensitivity to the chemotherapy drug cisplatin.
In IHC analysis of six human NSCLC cell lines, H2170 cells with four Cul4A copy numbers analysed using FISH showed strong Cul4A staining score (+++) ( Figure 6A ). H226 and H345 cells with three Cul4A copy numbers showed strong to moderate IHC staining score (+++ and ++, respectively). H838, A549 and H460 cells with two Cul4A copy numbers showed moderate IHC staining score (++). In contract, normal lung tissue showed weak Cul4A staining score (+/−) (data not shown). We believe that our mouse model represents, at least in part, a fraction of human NSCLC with amplified Cul4A copy number.
Our IHC analysis indicated that the level of p27 KIP1 expression was increased in lung tumours over-expressing Cul4A, suggesting that p27 KIP1 is probably not proteolysed by Cul4A-based E3 ubiquitin ligase in the lung tumours. This finding is supported by previous studies suggesting that p27 KIP1 is not a target degraded by the Cul4A-based E3 ubiquitin ligase [31, 32] . For instance, depletion of the Cul4A-RING ubiquitin ligase (E3) complexes did not immediately increase p27 KIP1 expression in the cells [31, 32] . In addition, p27 KIP1 expression was elevated in response to UV-irradiation, regardless the presence of functional Cul4A-based E3 ubiquitin ligase complex in the cells [32] . Together, these findings and ours all suggest that p27 KIP1 is not a target degraded by Cul4A-based E3 ubiquitin ligase. Because p27 KIP1 functions as a tumour suppressor and was strongly expressed in our Cul4A mouse model, knocking down the expression of p27 KIP1 in our mouse model could provide further insights into the biology of human cancers that over-express Cul4A. It has been shown that Cul4A-based E3 ubiquitin ligase complex is required for p16
INK4a activation in human lung cells [33] . In clinical studies, inactivation of p16 INK4a was reported in 40-70% of human NSCLC cases [34, 35] . Interestingly, p16
INK4a expression was not decreased in the lung tumours of our Cul4A mouse model, suggesting that down-regulation of p16
INK4a expression in this model could provide further insights into the biology of Cul4A-mediated tumourigenesis. Therefore, by crossing this mouse model with a p16
INK4a knockout strain, we generated a new mouse model that has p16
INK4a depletion and oncogenic Cul4A over-expression. This new model provides an excellent opportunity to improve our understanding of the biology of cancers in which Cul4A is over-expressed, including NSCLC, mesothelioma, breast cancer and skin carcinomas.
The results of our IHC analysis showed decreased expression of p19 ARF in the lung tumours over-expressing Cul4A. This finding suggests that degradation of p19 ARF protein occurred after Cul4A over-expression and that the loss of p19 ARF may contribute to tumour development in this mouse model. p21 CIP1 -deficient mice have been shown to develop different tumours in the mouse organs, including lung carcinomas [36] . Because Cul4A can target multiple different proteins for degradation (Figure 7) , the phenotype of Cul4A transgenic mice is expected to be more tumourigenic than that in the p21 CIP1 -de ficient mice. The role Cul4A plays in the initiation and development of lung tumours in our mouse model has implications for understanding cancer biology and introduces new avenues for therapeutic development targeting Cul4A. These possibilities are supported by recent findings that MLN4924, a small molecule that blocks the activation of Cullin-based E3 ubiquitin ligase, suppresses tumour cell growth [37] . The effect of MLN4924 in controlling the growth of lung tumours can be further investigated in our mouse model. To date, cisplatin, a platinum-based therapy, is one of the most commonly used chemotherapeutic agents in the treatment of NSCLC, but about 20% of patients experience a partial response to cisplatin [38, 39] . Our study found that the IC 50 of NSCLC cell line H2170 decreased more than two-fold when Cul4A transcription was knocked down before the cisplatin treatment, suggesting that Cul4A over-expression is associated with cisplatin resistance in the cancer cells. This possibility is supported by the fact that a combination therapy consisting of MLN4924 and cisplatin significantly reduces tumour burden in mice, a finding that also suggests a mechanism to induce cancer cell apoptosis by trigging ROS production to induce DNA damage in cancer cells [40] . Whether this mechanism is involved in the decreased cell viability in the H2170 cells treated with both Cul4A siRNA and cisplatin remains to be examined.
In summary, the Cul4A mouse model described here has many advantages over existing mouse models for cancer research. The ability to target specific organs through localized Ad-Cre infection can be useful to generate mouse models for studying the development of organ-specific tumours. Using this mouse model, we demonstrated for the first time that Cul4A is oncogenic in vivo and that the development of lung tumours can be induced by Cul4A over-expression. From these findings, we conclude that over-expression of Cul4A plays 122 YL Yang et al Figure 7 . Schematic explanation of potential mechanisms of initiation and progression of lung tumour in Ad-Cre-induced Cul4A transgenic mice. Lungs from the transgenic mice appear to be normal without tumour until Cul4A over-expression was induced by Ad-Cre. Lesions were observed in the lungs in which Cul4A was over-expressed, including alveolar oedema, lymphocyte aggregation and atypical epithelial cells. Decreased levels of p21 CIP1 , p19 ARF and CDT1 proteins and increased levels of PCNA, p27 KIP1 , p16
INK4a and pericentrin proteins contributed to cell-cycle defects and genomic instability, resulting in tumour development in the lungs in which Cul4A was over-expressed a role in tumour development in this mouse model ( Figure 7) . A better understanding of the mechanisms of Cul4A-mediated lung tumourigenesis in this mouse model could provide new insights into the biology of human cancers that over-express Cul4A and could contribute to future experimental therapies.
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The following supplementary material may be found in the online version of this article:
Supplementary materials and methods Figure S1 . Analysis of TCGA data of lung adenocarcinomas using the Oncomine database. Analysis of Cul4A copy number in the transgenic mouse tissues using qPCR and analysis of chromosomal and transcriptional levels of (B) p21 CIP1 and (C) CDT1 expression in mouse tumours and control mouse lungs using qPCR and qRT-PCR.
